{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:49:09Z","timestamp":1790812149436,"version":"4.1.0"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>In recent years, studies have shed light on the concept of risk heterogeneity among patients with severe hypertriglyceridemia (HTG). Several clinical risk factors for acute pancreatitis have been identified in this population, but the importance of different genetic factors above and beyond triglyceride concentration remains unclear. This review endeavours to summarize recent developments in this field.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Recent studies suggest that the molecular basis of severe HTG (polygenic susceptibility vs. rare pathogenic variants) can modulate the risk of acute pancreatitis independently of triglyceride level. Furthermore, a pancreatitis polygenic risk score has been developed and validated using data from the largest GWAS meta-analysis of acute pancreatitis published to date. In patients with severe HTG, a high polygenic susceptibility for pancreatitis was associated with a three-fold increased risk of acute pancreatitis compared with those with a lower polygenic risk score.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>In the past months, there have been substantial advances in understanding the prediction of acute pancreatitis in patients with severe HTG. However, further efforts at developing risk-stratification strategies and predictive models may help identifying the patients who would benefit most from early and effective interventions to reduce the risk of pancreatitis, including treatment with APOC3 inhibitors.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mol.0000000000000962","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T15:00:34Z","timestamp":1731078034000},"page":"55-60","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Genetic determinants of pancreatitis risk in hypertriglyceridemia"],"prefix":"10.1097","volume":"36","author":[{"given":"Martine","family":"Paquette","sequence":"first","affiliation":[{"name":"Genetic Dyslipidemias Clinic of the Montreal Clinical Research Institute, Montreal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon-Pierre","family":"Guay","sequence":"additional","affiliation":[{"name":"Division of Medical Genetics, Department of Pediatric, Faculty of Medicine and Health Sciences, Universit\u00e9 de Sherbrooke, Sherbrooke"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Baass","sequence":"additional","affiliation":[{"name":"Genetic Dyslipidemias Clinic of the Montreal Clinical Research Institute, Montreal"},{"name":"Department of Medicine, Divisions of Experimental Medicine and Medical Biochemistry, McGill University, Montreal, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,11,8]]},"reference":[{"key":"R1-20250414","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12944-017-0511-9","article-title":"Severe hypertriglyceridemia in Norway: prevalence, clinical and genetic characteristics","volume":"16","author":"Retterst\u00f8l","year":"2017","journal-title":"Lipids Health Dis"},{"key":"R2-20250414","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12933-022-01525-5","article-title":"Elevated plasma triglyceride concentration and risk of adverse clinical outcomes in 1.5 million people: a CALIBER linked electronic health record study","volume":"21","author":"Patel","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"R3-20250414","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12944-021-01517-6","article-title":"Incidence, predictors and patterns of care of patients with very severe hypertriglyceridemia in Ontario, Canada: a population-based cohort study","volume":"20","author":"Berberich","year":"2021","journal-title":"Lipids Health Dis"},{"key":"R4-20250414","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jacl.2010.11.004","article-title":"Etiology and risk of lactescent plasma and severe hypertriglyceridemia","volume":"5","author":"Tremblay","year":"2011","journal-title":"J Clin Lipidol"},{"key":"R5-20250414","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jacl.2020.01.014","article-title":"Chylomicronemia syndrome: familial or not?","volume":"14","author":"Warden","year":"2020","journal-title":"J Clin Lipidol"},{"key":"R6-20250414","doi-asserted-by":"crossref","first-page":"e1332","DOI":"10.1210\/clinem\/dgaa838","article-title":"10-year comparative follow-up of familial versus multifactorial chylomicronemia syndromes","volume":"106","author":"Belhassen","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"R7-20250414","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jacl.2023.05.096","article-title":"Nonalcoholic fatty liver disease in patients with chylomicronemia syndromes","volume":"17","author":"De Villers-Lacasse","year":"2023","journal-title":"J Clin Lipidol"},{"key":"R8-20250414","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jacl.2022.05.064","article-title":"Prevalence, severity and management of hypertriglyceridemia-associated pancreatitis; a 7-year retrospective cohort study at Canadian quaternary care hospitals","volume":"16","author":"Hassanloo","year":"2022","journal-title":"J Clin Lipidol"},{"key":"R9-20250414","doi-asserted-by":"crossref","first-page":"17936","DOI":"10.1038\/s41598-020-74943-8","article-title":"Assessment of the course of acute pancreatitis in the light of aetiology: a systematic review and meta-analysis","volume":"10","author":"B\u00e1lint","year":"2020","journal-title":"Sci Rep"},{"key":"R10-20250414","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.3390\/jcm9123954","article-title":"Incidence and management of hypertriglyceridemia-associated acute pancreatitis: a prospective case series in a single Australian tertiary centre","volume":"9","author":"Tan","year":"2020","journal-title":"J Clin Med"},{"key":"R11-20250414","doi-asserted-by":"crossref","first-page":"1490.e1","DOI":"10.1053\/j.gastro.2015.07.066","article-title":"Frequency of progression from acute to chronic pancreatitis and risk factors: a meta-analysis","volume":"149","author":"Sankaran","year":"2015","journal-title":"Gastroenterology"},{"key":"R12-20250414","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/ajg.2017.218","article-title":"Chronic pancreatitis and pancreatic cancer risk: a systematic review and meta-analysis","volume":"112","author":"Kirkeg\u00e5rd","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"R13-20250414","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3111\/13696998.2013.779277","article-title":"Medical resource use and costs associated with chylomicronemia","volume":"16","author":"Gaudet","year":"2013","journal-title":"J Med Econ"},{"key":"R14-20250414","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/MPA.0b013e3180cac24b","article-title":"Direct medical costs of acute pancreatitis hospitalizations in the United States","volume":"35","author":"Fagenholz","year":"2007","journal-title":"Pancreas"},{"key":"R15-20250414","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.atherosclerosis.2018.12.019","article-title":"Chylomicronemia: differences between familial chylomicronemia syndrome and multifactorial chylomicronemia","volume":"283","author":"Paquette","year":"2019","journal-title":"Atherosclerosis"},{"key":"R16-20250414","doi-asserted-by":"crossref","first-page":"e3473","DOI":"10.1210\/clinem\/dgab360","article-title":"Rare variants in triglycerides-related genes increase pancreatitis risk in multifactorial chylomicronemia syndrome","volume":"106","author":"Paquette","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"R17-20250414","doi-asserted-by":"crossref","first-page":"117528","DOI":"10.1016\/j.atherosclerosis.2024.117528","article-title":"Pancreatitis risk in genetic subtypes of multifactorial chylomicronemia syndrome","volume":"392","author":"Berberich","year":"2024","journal-title":"Atherosclerosis"},{"key":"R18-20250414","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","article-title":"Clinical review on triglycerides","volume":"41","author":"Laufs","year":"2020","journal-title":"Eur Heart J"},{"key":"R19-20250414","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/eurheartj\/ehad845","article-title":"Genetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic risk","volume":"45","author":"Gobeil","year":"2024","journal-title":"Eur Heart J"},{"key":"R20-20250414","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.pan.2019.08.002","article-title":"Subsets associated with developing acute pancreatitis in patients with severe hypertriglyceridemia and the severity of pancreatitis","volume":"19","author":"Jo","year":"2019","journal-title":"Pancreatology"},{"key":"R21-20250414","first-page":"2620750","article-title":"Diabetes and younger age are vital and independent risk factors for acute pancreatitis in patients with severe hypertriglyceridemia","volume":"2019","author":"Li","year":"2019","journal-title":"Biomed Res Int"},{"key":"R22-20250414","doi-asserted-by":"crossref","first-page":"817","DOI":"10.4158\/EP-2018-0599","article-title":"External validation of a predictive model for acute pancreatitis risk in patients with severe hypertriglyceridemia","volume":"25","author":"Morkos","year":"2019","journal-title":"Endocr Pract"},{"key":"R23-20250414","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/MOL.0000000000000866","article-title":"Genetic determinants of pancreatitis: relevance in severe hypertriglyceridemia","volume":"34","author":"Hang","year":"2023","journal-title":"Curr Opin Lipidol"},{"key":"R24-20250414","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1038\/s41598-024-56946-x","article-title":"Lipid levels and risk of acute pancreatitis using bidirectional Mendelian randomization","volume":"14","author":"Wang","year":"2024","journal-title":"Sci Rep"},{"key":"R25-20250414","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jacl.2018.10.006","article-title":"Severe hypertriglyceridemia is primarily polygenic","volume":"13","author":"Dron","year":"2019","journal-title":"J Clin Lipidol"},{"key":"R26-20250414","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jacl.2023.08.003","article-title":"Variability of longitudinal triglyceride phenotype in patients heterozygous for pathogenic APOA5 variants","volume":"17","author":"Perera","year":"2023","journal-title":"J Clin Lipidol"},{"key":"R27-20250414","doi-asserted-by":"crossref","first-page":"117489","DOI":"10.1016\/j.atherosclerosis.2024.117489","article-title":"Acute pancreatitis risk in multifactorial chylomicronemia syndrome depends on the molecular cause of severe hypertriglyceridemia","volume":"392","author":"Guay","year":"2024","journal-title":"Atherosclerosis"},{"key":"R28-20250414","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1161\/ATVBAHA.122.318445","article-title":"Genetic testing for hypertriglyceridemia in academic lipid clinics: implications for precision medicine-brief report","volume":"42","author":"Deshotels","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R29-20250414","doi-asserted-by":"crossref","first-page":"2265939","DOI":"10.1080\/07853890.2023.2265939","article-title":"Comprehensive review on the pathogenesis of hypertriglyceridaemia-associated acute pancreatitis","volume":"55","author":"Qiu","year":"2023","journal-title":"Ann Med"},{"key":"R30-20250414","doi-asserted-by":"crossref","first-page":"e700","DOI":"10.1097\/MPA.0000000000002364","article-title":"Research progress on the mechanism of acute hypertriglyceridemic pancreatitis","volume":"53","author":"Meng","year":"2024","journal-title":"Pancreas"},{"key":"R31-20250414","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1136\/gutjnl-2017-314454","article-title":"All members of the PanEuropean Working group on ACP. Genome-wide association study identifies inversion in the CTRB1-CTRB2 locus to modify risk for alcoholic and nonalcoholic chronic pancreatitis","volume":"67","author":"Rosendahl","year":"2018","journal-title":"Gut"},{"key":"R32-20250414","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/ng.2466","article-title":"Common genetic variants in the CLDN2 and PRSS1-PRSS2 loci alter risk for alcohol-related and sporadic pancreatitis","volume":"44","author":"Whitcomb","year":"2012","journal-title":"Nat Genet"},{"key":"R33-20250414","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.pan.2022.03.007","article-title":"Colocalization analysis of pancreas eQTLs with risk loci from alcoholic and novel nonalcoholic chronic pancreatitis GWAS suggests potential disease causing mechanisms","volume":"22","author":"Schmidt","year":"2022","journal-title":"Pancreatology"},{"key":"R34-20250414","doi-asserted-by":"crossref","first-page":"953.e3","DOI":"10.1053\/j.gastro.2023.01.028","article-title":"Proteome-wide Mendelian randomization identifies causal links between blood proteins and acute pancreatitis","volume":"164","author":"Bourgault","year":"2023","journal-title":"Gastroenterology"},{"key":"R35-20250414","doi-asserted-by":"crossref","first-page":"e413","DOI":"10.1016\/j.jacl.2024.02.007","article-title":"Pancreatitis polygenic risk score is associated with acute pancreatitis in multifactorial chylomicronemia syndrome","volume":"18","author":"Guay","year":"2024","journal-title":"J Clin Lipidol"},{"key":"R36-20250414","doi-asserted-by":"crossref","DOI":"10.1111\/jgh.16759","article-title":"Pancreatitis polygenic risk score is independently associated with all-cause acute pancreatitis risk in the UK Biobank","author":"Guay","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"key":"R37-20250414","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/clinchem\/hvad094","article-title":"Hypertriglyceridemia-associated pancreatitis: new concepts and potential mechanisms","volume":"69","author":"Hansen","year":"2023","journal-title":"Clin Chem"},{"key":"R38-20250414","first-page":"dgae103","article-title":"High hsCRP concentration is associated with acute pancreatitis in multifactorial chylomicronemia syndrome","author":"Guay","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"R39-20250414","doi-asserted-by":"crossref","first-page":"1380998","DOI":"10.3389\/fcimb.2024.1380998","article-title":"Gut microbiota influence acute pancreatitis through inflammatory proteins: a Mendelian randomization analysis","volume":"14","author":"Huang","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"key":"R40-20250414","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"R41-20250414","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jacl.2012.08.007","article-title":"Clinical and economic benefits observed when follow-up triglyceride levels are less than 500\u200amg\/dL in patients with severe hypertriglyceridemia","volume":"6","author":"Christian","year":"2012","journal-title":"J Clin Lipidol"},{"key":"R42-20250414","doi-asserted-by":"crossref","first-page":"36.e1","DOI":"10.1016\/j.amjmed.2013.09.018","article-title":"Determining triglyceride reductions needed for clinical impact in severe hypertriglyceridemia","volume":"127","author":"Christian","year":"2014","journal-title":"Am J Med"},{"key":"R43-20250414","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.nutres.2022.02.001","article-title":"Both low-fat and low-carbohydrate diets reduce triglyceride concentration in subjects with multifactorial chylomicronemia syndrome: a randomized crossover study","volume":"101","author":"Fantino","year":"2022","journal-title":"Nutr Res"},{"key":"R44-20250414","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1001\/jama.2012.8439","article-title":"Lipid-modifying therapies and risk of pancreatitis: a meta-analysis","volume":"308","author":"Preiss","year":"2012","journal-title":"JAMA"},{"key":"R45-20250414","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","article-title":"Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"9","author":"Gouni-Berthold","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R46-20250414","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N Engl J Med"},{"key":"R47-20250414","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/17446651.2024.2365787","article-title":"Etiology and emerging treatments for familial chylomicronemia syndrome","volume":"19","author":"Spagnuolo","year":"2024","journal-title":"Expert Rev Endocrinol Metab"},{"key":"R48-20250414","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa2402309","article-title":"Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk","volume":"390","author":"Bergmark","year":"2024","journal-title":"N Engl J Med"},{"key":"R49-20250414","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","article-title":"Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 Randomized Clinical Trial","volume":"9","author":"Gaudet","year":"2024","journal-title":"JAMA Cardiol"},{"key":"R50-20250414","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N Engl J Med"},{"key":"R51-20250414","article-title":"PALISADE Study Group","author":"Watts","year":"2024","journal-title":"N Engl J Med"},{"key":"R52-20250414","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41591-023-02222-w","article-title":"Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial","volume":"29","author":"Rosenson","year":"2023","journal-title":"Nat Med"},{"key":"R53-20250414","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s11883-023-01179-y","article-title":"Inhibition of angiopoietin-like protein 3 or 3\/8 complex and ApoC-III in severe hypertriglyceridemia","volume":"25","author":"Larouche","year":"2023","journal-title":"Curr Atheroscler Rep"}],"container-title":["Current Opinion in Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOL.0000000000000962","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T10:00:23Z","timestamp":1744624823000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOL.0000000000000962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,8]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mol.0000000000000962","relation":{},"ISSN":["0957-9672","1473-6535"],"issn-type":[{"value":"0957-9672","type":"print"},{"value":"1473-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,8]]}}}